---
document_datetime: 2025-12-02 06:13:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/aldara.html
document_name: aldara.html
version: success
processing_time: 0.1319253
conversion_datetime: 2025-12-28 19:45:24.695169
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Aldara

[RSS](/en/individual-human-medicine.xml/66754)

##### Authorised

This medicine is authorised for use in the European Union

imiquimod Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78097)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Aldara?

Aldara is a cream containing the active substance imiquimod. It is available as 250-mg sachets, each containing 12.5 mg imiquimod (5%).

## What is Aldara used for?

Aldara is used in adults to treat the following skin diseases:

- warts on the genitals and around the anus;
- small basal-cell carcinomas (slow-growing types of skin cancer);
- actinic keratoses of the face and scalp (precancerous, abnormal skin growths that develop after too much exposure to sunlight), in patients whose immune system is working normally. It is used when other treatments such as cryotherapy (freezing) cannot be used.

The medicine can only be obtained with a prescription.

## How is Aldara used?

The number of times Aldara is applied and the duration of treatment depend on the condition being treated.

- For genital warts, Aldara is applied three times a week for up to 16 weeks.
- For small basal cell carcinomas, the cream is applied five times a week for six weeks.
- For actinic keratoses, it is applied three times a week, for one or two four-week courses, with four weeks between courses.

The cream is applied in a thin layer to the affected areas of skin before sleeping, so that it remains on the skin for a suitable length of time (about eight hours) before being washed off. For further information, see the package leaflet.

## How does Aldara work?

The active substance in Aldara cream, imiquimod, is an immune-response modifier. This means that it uses the immune system, the body's natural defences, to bring about its effect. When imiquimod is applied to the skin, it acts locally on the immune system to trigger the release of cytokines, including interferon. These substances help to kill the viruses that cause warts or the abnormal cells in the skin that develop into skin cancer or keratoses.

## How has Aldara been studied?

In all studies, Aldara was compared with placebo (the same cream but without the active substance).

- Aldara has been studied in 923 patients with genital warts in four main studies lasting 16 weeks. The main measure of effectiveness was the number of patients with total clearance of treated warts.
- Aldara has also been studied in 724 patients with small basal-cell carcinomas in two studies where patients were treated for six weeks, and used Aldara or placebo either five times a week or every day. The main measure of effectiveness was the number of patients with total clearance of the tumours after 12 weeks.
- Aldara has also been studied in patients with actinic keratoses in two studies involving a total of 505 patients. The main measure of effectiveness was the number of patients whose keratoses had cleared after one or two four-week courses of treatment.

## What benefit has Aldara shown during the studies?

In all studies, Aldara was more effective than placebo.

- In the treatment of genital warts, the total clearance rate across the four main studies was 15 to 52% in the Aldara-treated patients, compared with 3 to 18% in the placebo-treated patients.
- When the results of the two studies in basal-cell carcinoma were looked at together, total clearance was seen in 66 to 80% of Aldara-treated patients compared with 0 to 3% in the placebo group. There were no differences between the two dose frequencies.
- In actinic keratoses, complete clearance after one or two courses of treatment was seen in 54 and 55% of Aldara-treated patients in the two studies, compared with 15 and 2% in the placebo-treated patients.

## What is the risk associated with Aldara?

The most common side effect with Aldara (seen in more that 1 patient in 10) is a reaction at the site of application of the cream (pain or itching). For the full list of all side effects reported with Aldara, see the package leaflet.

Aldara should not be used in people who may be hypersensitive (allergic) to imiquimod or any of the other ingredients.

## Why has Aldara been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Aldara's benefits are greater than its risks for the treatment of external genital and perianal warts (condylomata acuminata), small basal-cell carcinomas and non-hyperkeratotic, non-hypertrophic actinic keratoses in immunocompetent adult patients when other topical treatment options are contraindicated or less appropriate. The Committee recommended that Aldara be given marketing authorisation.

## Other information about Aldara

The European Commission granted a marketing authorisation valid throughout the European Union for Aldara on 18 September 1998. The marketing authorisation was renewed on 18 September 2003 and on 18 September 2008. The marketing-authorisation holder is Meda AB.

Aldara : EPAR - Summary for the public

English (EN) (45.38 KB - PDF)

**First published:** 08/10/2008

**Last updated:** 08/10/2008

[View](/en/documents/overview/aldara-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-914)

български (BG) (170.25 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/bg/documents/overview/aldara-epar-summary-public_bg.pdf)

español (ES) (46.79 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/es/documents/overview/aldara-epar-summary-public_es.pdf)

čeština (CS) (162.32 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/cs/documents/overview/aldara-epar-summary-public_cs.pdf)

dansk (DA) (46.84 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/da/documents/overview/aldara-epar-summary-public_da.pdf)

Deutsch (DE) (47.51 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/de/documents/overview/aldara-epar-summary-public_de.pdf)

eesti keel (ET) (46.2 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/et/documents/overview/aldara-epar-summary-public_et.pdf)

ελληνικά (EL) (163.47 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/el/documents/overview/aldara-epar-summary-public_el.pdf)

français (FR) (44.67 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/fr/documents/overview/aldara-epar-summary-public_fr.pdf)

italiano (IT) (47.2 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/it/documents/overview/aldara-epar-summary-public_it.pdf)

latviešu valoda (LV) (164.19 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/lv/documents/overview/aldara-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (158.88 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/lt/documents/overview/aldara-epar-summary-public_lt.pdf)

magyar (HU) (154.46 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/hu/documents/overview/aldara-epar-summary-public_hu.pdf)

Malti (MT) (165.02 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/mt/documents/overview/aldara-epar-summary-public_mt.pdf)

Nederlands (NL) (46.88 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/nl/documents/overview/aldara-epar-summary-public_nl.pdf)

polski (PL) (168.97 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/pl/documents/overview/aldara-epar-summary-public_pl.pdf)

português (PT) (48.45 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/pt/documents/overview/aldara-epar-summary-public_pt.pdf)

română (RO) (153.81 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/ro/documents/overview/aldara-epar-summary-public_ro.pdf)

slovenčina (SK) (158.39 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/sk/documents/overview/aldara-epar-summary-public_sk.pdf)

slovenščina (SL) (148.67 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/sl/documents/overview/aldara-epar-summary-public_sl.pdf)

Suomi (FI) (46.59 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/fi/documents/overview/aldara-epar-summary-public_fi.pdf)

svenska (SV) (46.46 KB - PDF)

**First published:**

08/10/2008

**Last updated:**

08/10/2008

[View](/sv/documents/overview/aldara-epar-summary-public_sv.pdf)

## Product information

Aldara : EPAR - Product Information

English (EN) (745.92 KB - PDF)

**First published:** 14/09/2009

**Last updated:** 18/07/2025

[View](/en/documents/product-information/aldara-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-457)

български (BG) (405.99 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/bg/documents/product-information/aldara-epar-product-information_bg.pdf)

español (ES) (399.13 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/es/documents/product-information/aldara-epar-product-information_es.pdf)

čeština (CS) (370.71 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/cs/documents/product-information/aldara-epar-product-information_cs.pdf)

dansk (DA) (453.89 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/da/documents/product-information/aldara-epar-product-information_da.pdf)

Deutsch (DE) (402.83 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/de/documents/product-information/aldara-epar-product-information_de.pdf)

eesti keel (ET) (234 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/et/documents/product-information/aldara-epar-product-information_et.pdf)

ελληνικά (EL) (449.14 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/el/documents/product-information/aldara-epar-product-information_el.pdf)

français (FR) (791.17 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/fr/documents/product-information/aldara-epar-product-information_fr.pdf)

hrvatski (HR) (502.96 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/hr/documents/product-information/aldara-epar-product-information_hr.pdf)

íslenska (IS) (548.48 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/is/documents/product-information/aldara-epar-product-information_is.pdf)

italiano (IT) (369.03 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/it/documents/product-information/aldara-epar-product-information_it.pdf)

latviešu valoda (LV) (281.08 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/lv/documents/product-information/aldara-epar-product-information_lv.pdf)

lietuvių kalba (LT) (791.58 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/lt/documents/product-information/aldara-epar-product-information_lt.pdf)

magyar (HU) (418.97 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/hu/documents/product-information/aldara-epar-product-information_hu.pdf)

Malti (MT) (429.52 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/mt/documents/product-information/aldara-epar-product-information_mt.pdf)

Nederlands (NL) (483.5 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/nl/documents/product-information/aldara-epar-product-information_nl.pdf)

norsk (NO) (455.95 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/no/documents/product-information/aldara-epar-product-information_no.pdf)

polski (PL) (566.58 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/pl/documents/product-information/aldara-epar-product-information_pl.pdf)

português (PT) (360.89 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/pt/documents/product-information/aldara-epar-product-information_pt.pdf)

română (RO) (468.33 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/ro/documents/product-information/aldara-epar-product-information_ro.pdf)

slovenčina (SK) (345.2 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/sk/documents/product-information/aldara-epar-product-information_sk.pdf)

slovenščina (SL) (576.49 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/sl/documents/product-information/aldara-epar-product-information_sl.pdf)

Suomi (FI) (739.51 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/fi/documents/product-information/aldara-epar-product-information_fi.pdf)

svenska (SV) (471.78 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

18/07/2025

[View](/sv/documents/product-information/aldara-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000286628 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Aldara : EPAR - All Authorised presentations

English (EN) (8.03 KB - PDF)

**First published:** 14/09/2009

**Last updated:** 14/09/2009

[View](/en/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-572)

български (BG) (46.98 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/bg/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_bg.pdf)

español (ES) (8.54 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/es/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29.26 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/cs/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (8.54 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/da/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (8.33 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/de/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (8.31 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/et/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/el/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_el.pdf)

français (FR) (8.54 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/fr/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (70.74 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/hr/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (8.63 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/is/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_is.pdf)

italiano (IT) (8.12 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/it/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (32.85 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/lv/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (29.61 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/lt/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.35 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/hu/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.71 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/mt/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (8.4 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/nl/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (8.57 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/no/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.35 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/pl/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_pl.pdf)

português (PT) (8.73 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/pt/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_pt.pdf)

română (RO) (29.89 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/ro/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (19.64 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/sk/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (8.28 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/sl/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (8.29 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/fi/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (8.59 KB - PDF)

**First published:**

14/09/2009

**Last updated:**

14/09/2009

[View](/sv/documents/all-authorised-presentations/aldara-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Aldara Active substance imiquimod International non-proprietary name (INN) or common name imiquimod Therapeutic area (MeSH)

- Condylomata Acuminata
- Keratosis
- Keratosis, Actinic
- Carcinoma, Basal Cell

Anatomical therapeutic chemical (ATC) code D06BB10

### Pharmacotherapeutic group

Antibiotics and chemotherapeutics for dermatological use

### Therapeutic indication

Imiquimod cream is indicated for the topical treatment of :

- External genital and perianal warts (condylomata acuminata) in adults.
- Small superficial basal cell carcinomas (sBCCs) in adults.
- Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

## Authorisation details

EMA product number EMEA/H/C/000179 Marketing authorisation holder

Viatris Healthcare Limited

Damastown Industrial Park Mulhuddart Dublin 15 Dublin Ireland

Opinion adopted 27/05/1998 Marketing authorisation issued 18/09/1998 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Aldara : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.93 KB - PDF)

**First published:** 18/07/2025

[View](/en/documents/procedural-steps-after/aldara-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Aldara : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (200.58 KB - PDF)

**First published:** 14/09/2009

**Last updated:** 18/07/2025

[View](/en/documents/procedural-steps-after/aldara-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Aldara-H-C-PSUSA-00001729/202001 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/652772/2020

English (EN) (130.95 KB - PDF)

**First published:** 15/12/2020

[View](/en/documents/scientific-conclusion/aldara-h-c-psusa-00001729202001-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Aldara-H-C-179-II-0026 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (201 KB - PDF)

**First published:** 09/01/2007

**Last updated:** 09/01/2007

[View](/en/documents/scientific-discussion-variation/aldara-h-c-179-ii-0026-epar-scientific-discussion-variation_en.pdf)

Aldara : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (89.97 KB - PDF)

**First published:** 21/07/2006

**Last updated:** 21/07/2006

[View](/en/documents/steps-after-cutoff/aldara-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

Aldara-H-C-179-II-0020 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (292 KB - PDF)

**First published:** 21/07/2006

**Last updated:** 21/07/2006

[View](/en/documents/scientific-discussion-variation/aldara-h-c-179-ii-0020-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Aldara : EPAR - Scientific Discussion

English (EN) (193.47 KB - PDF)

**First published:** 21/07/2006

**Last updated:** 21/07/2006

[View](/en/documents/scientific-discussion/aldara-epar-scientific-discussion_en.pdf)

Aldara : EPAR - Procedural steps taken before authorisation

English (EN) (91.65 KB - PDF)

**First published:** 21/07/2006

**Last updated:** 21/07/2006

[View](/en/documents/procedural-steps/aldara-epar-procedural-steps-taken-authorisation_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Aldara : EPAR - Product information - tracked changes

English (EN) (332 KB - DOC)

**First published:** 18/07/2025

[View](/en/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_en.doc)

[Other languages (24)](#file-language-dropdown-875)

български (BG) (144.16 KB - DOCX)

**First published:**

18/07/2025

[View](/bg/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_bg.docx)

español (ES) (147.17 KB - DOCX)

**First published:**

18/07/2025

[View](/es/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_es.docx)

čeština (CS) (141.15 KB - DOCX)

**First published:**

18/07/2025

[View](/cs/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (360 KB - DOC)

**First published:**

18/07/2025

[View](/da/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_da.doc)

Deutsch (DE) (369.5 KB - DOC)

**First published:**

18/07/2025

[View](/de/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_de.doc)

eesti keel (ET) (353.5 KB - DOC)

**First published:**

18/07/2025

[View](/et/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (462.5 KB - DOC)

**First published:**

18/07/2025

[View](/el/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_el.doc)

français (FR) (343.5 KB - DOC)

**First published:**

18/07/2025

[View](/fr/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_fr.doc)

hrvatski (HR) (155.87 KB - DOCX)

**First published:**

18/07/2025

[View](/hr/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (135.79 KB - DOCX)

**First published:**

18/07/2025

[View](/is/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_is.docx)

italiano (IT) (389.5 KB - DOC)

**First published:**

18/07/2025

[View](/it/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (455 KB - DOC)

**First published:**

18/07/2025

[View](/lv/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_lv.doc)

lietuvių kalba (LT) (405.5 KB - DOC)

**First published:**

18/07/2025

[View](/lt/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (420 KB - DOC)

**First published:**

18/07/2025

[View](/hu/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (440 KB - DOC)

**First published:**

18/07/2025

[View](/mt/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_mt.doc)

Nederlands (NL) (364 KB - DOC)

**First published:**

18/07/2025

[View](/nl/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (135.59 KB - DOCX)

**First published:**

18/07/2025

[View](/no/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_no.docx)

polski (PL) (437 KB - DOC)

**First published:**

18/07/2025

[View](/pl/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_pl.doc)

português (PT) (377 KB - DOC)

**First published:**

18/07/2025

[View](/pt/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_pt.doc)

română (RO) (136.24 KB - DOCX)

**First published:**

18/07/2025

[View](/ro/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (443.5 KB - DOC)

**First published:**

18/07/2025

[View](/sk/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (395.5 KB - DOC)

**First published:**

18/07/2025

[View](/sl/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_sl.doc)

Suomi (FI) (366.5 KB - DOC)

**First published:**

18/07/2025

[View](/fi/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (136.89 KB - DOCX)

**First published:**

18/07/2025

[View](/sv/documents/product-information-tracked-changes/aldara-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/07/2025

## Share this page

[Back to top](#main-content)